Journal of Neuroinformatics and Neuroimaging

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Journal of Neuroinformatics and Neuroimaging (2023) Volume 8, Issue 3

COVID-19 and muscular involvement in neuromuscular diseases

Scouiller Knak*

Department of Neurology

*Corresponding Author:
Brem Rourke
Department of Neurology
Rutgers University
USA
E-mail:knak.s@Rutgers.edu

Received:29-May-2023, Manuscript No. AANN-23-99721; Editor assigned:01-Jun-2023, PreQC No. AANN-23-99721 (PQ); Reviewed:15-Jun-2023, QC No. AANN-23-99721; Revised:19-Jun-2023, Manuscript No. AANN-23-99721 (R); Published:26-Jun-2023, DOI:10.35841/ aann-8.3.154

Citation: Knak S. COVID-19 and muscular involvement in neuromuscular diseases. J NeuroInform Neuroimaging. 2023;8(3):154

Visit for more related articles at Journal of Neuroinformatics and Neuroimaging

Abstract

COVID-19, caused by SARS-CoV-2, has emerged as a global health crisis with widespread impacts on multiple organ systems. In addition to respiratory complications, there is emerging evidence of muscular involvement in COVID-19 patients, particularly in individuals with pre-existing neuromuscular diseases. This abstract summarizes the current understanding of the interaction between COVID-19 and neuromuscular diseases, highlighting the potential exacerbation of muscle weakness, myopathy, and neuromuscular junction dysfunction. We discuss the implications of COVID-19 on disease progression, management strategies, and the need for further research to better comprehend the intricate interplay between SARS-CoV-2 infection and neuromuscular conditions.

Abstract

COVID-19, caused by SARS-CoV-2, has emerged as a global health crisis with widespread impacts on multiple organ systems. In addition to respiratory complications, there is emerging evidence of muscular involvement in COVID-19 patients, particularly in individuals with pre-existing neuromuscular diseases. This abstract summarizes the current understanding of the interaction between COVID-19 and neuromuscular diseases, highlighting the potential exacerbation of muscle weakness, myopathy, and neuromuscular junction dysfunction. We discuss the implications of COVID-19 on disease progression, management strategies, and the need for further research to better comprehend the intricate interplay between SARS-CoV-2 infection and neuromuscular conditions

Keywords

Neuromuscular diseases, COVID-19, Electromyography, Muscle imaging

Introduction

The COVID-19 pandemic has had a significant impact on global health, affecting millions of individuals worldwide. While the respiratory symptoms associated with COVID-19 are widely recognized, the virus can also affect other organ systems, including the muscles. For individuals with neuromuscular diseases, the potential involvement of their already compromised muscles poses unique challenges and considerations. This article explores the impact of COVID-19 on individuals with neuromuscular diseases and highlights the importance of tailored care for this vulnerable population

Neuromuscular diseases

Neuromuscular diseases encompass a diverse group of conditions characterized by dysfunction or degeneration of the nerves that control voluntary muscles. These diseases can affect various aspects of muscle function, including strength, coordination, and endurance. Examples of neuromuscular diseases include muscular dystrophy, amyotrophic lateral sclerosis (ALS), myasthenia gravis, and spinal muscular atrophy [1].

The link between COVID-19 and muscular involvement

COVID-19 primarily affects the respiratory system, causing symptoms such as cough, shortness of breath, and pneumonia. However, evidence suggests that the virus can also affect skeletal muscles directly, leading to muscle pain, weakness, and fatigue. The exact mechanisms underlying this muscle involvement are still being investigated but may involve direct viral invasion, systemic inflammation, or immune-mediated processes.

For individuals with pre-existing neuromuscular diseases, the impact of COVID-19 on muscle function can be particularly severe. These individuals often have compromised muscle strength and respiratory function, making them more vulnerable to respiratory complications and muscle deconditioning. Furthermore, the systemic inflammation and immune responses triggered by COVID-19 can potentially worsen the progression of underlying neuromuscular diseases [2].

Clinical implications and challenges

The intersection of COVID-19 and neuromuscular diseases presents unique challenges in terms of clinical management and care. Given the heterogeneity of neuromuscular diseases, each condition requires an individualized approach. Healthcare professionals must be aware of the specific needs and risks associated with each patient's underlying neuromuscular disease when managing COVID-19 cases [3].

Respiratory support: Individuals with neuromuscular diseases often rely on respiratory support devices, such as ventilators or non-invasive ventilation, to maintain adequate breathing. COVID-19 can exacerbate respiratory symptoms, leading to increased reliance on these devices and potential shortages of ventilatory support resources. It is crucial to ensure timely access to appropriate respiratory support for individuals with neuromuscular diseases who contract COVID-19.

Rehabilitation and physical therapy: Muscle weakness and deconditioning are common consequences of COVID-19, affecting both the general population and individuals with neuromuscular diseases. However, for individuals with pre-existing neuromuscular conditions, the impact of muscle deconditioning can be particularly profound. Rehabilitation and physical therapy programs should be tailored to address the unique needs and limitations of individuals with neuromuscular diseases to optimize their functional recovery [4].

Emotional and mental well-being: The COVID-19 pandemic has taken a toll on the mental health of individuals worldwide. For individuals with neuromuscular diseases, the pandemic-induced stress and social isolation can further exacerbate emotional and mental well-being challenges. Healthcare providers should prioritize holistic care, providing psychological support and resources to help individuals cope with the psychological impact of both the pandemic and their underlying condition.

Vaccination and prevention: Vaccination against COVID-19 is of paramount importance for individuals with neuromuscular diseases. These individuals are often at increased risk of severe illness and complications if infected. Healthcare providers should prioritize vaccination efforts for this vulnerable population, taking into account any specific considerations related to their underlying neuromuscular diseases. Additionally, individuals with neuromuscular diseases should continue to adhere to preventive measures, such as mask-wearing, hand hygiene, and social distancing, to reduce the risk of contracting COVID-19 [5].

Conclusion

COVID-19 poses unique challenges for individuals with neuromuscular diseases due to the potential involvement of their already compromised muscles. Understanding the implications of COVID-19 on neuromuscular function is crucial for providing appropriate care and support to this vulnerable population. Tailored management strategies, including respiratory support, rehabilitation, and mental health support, can help minimize the impact of COVID-19 on individuals with neuromuscular diseases. Continued research and collaboration among healthcare providers, researchers, and caregivers are essential to advance our understanding of the interaction between COVID-19 and neuromuscular diseases. By integrating these findings into clinical practice, we can optimize care and improve outcomes for individuals with neuromuscular diseases in the context of the ongoing pandemic and beyond.

References

  1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis.. J Med Virol. 2020;92(4):418-23.

    2. Indexed at, Google Scholar,Cross Ref

  2. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832.

    3. Indexed at, Google Scholar, Cross Ref

  3. Paliwal VK, Garg RK, Gupta A, et al. Neuromuscular presentations in patients with COVID-19 . J Neurol Sci. 2020;41:3039-56.

    4. Indexed at, Google Scholar, Cross Ref

  4. Guidon AC, Amato AA. COVID-19 and neuromuscular disorders . Neurology. 2020;94(22):959-69.

    5. Indexed at, Google Scholar, Cross Ref

  5. Liguori S, Moretti A, Paoletta M, et al. . Rehabilitation of neuromuscular diseases during COVID-19: Pitfalls and opportunities.. Front Neurol. 2021;12:626319.

    6. Indexed at, Google Scholar, Cross Ref

Get the App